PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds
PolarityTE to Present at Military Health System Research Symposium on Platform Technology for Treatment of Traumatic and Chronic Wounds |
[16-August-2019] |
SALT LAKE CITY, Aug. 16, 2019 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ: PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced that it will present data on the potential for SkinTEâ„¢ and OsteoTEâ„¢ to address military-related traumas and chronic wounds at the Military Health System Research Symposium on August 21, 2019, in Kissimmee, FL.
SkinTE is a first-of-its-kind autologous, homologous human cellular and tissue-based product designed to regenerate full-thickness, functional skin for the repair, reconstruction and replacement of a patient's own skin. OsteoTE, based on the same platform technology, is an autologous, homologous human cellular and tissue-based product intended to repair, reconstruct, replace and supplement bone. "PolarityTE is committed to advancing research and developing potential new treatment options for our armed forces and veterans to help them recover from traumatic and chronic wounds and burns," said Nikolai Sopko, MD, PhD, Chief Scientific Officer, PolarityTE. "We will continue to pursue opportunities and synergies with the defense community in hopes that we will make a true impact on treatment options for these patients and providers." The following poster will be presented on August 21, 2019, from 10:00am-12:00pm:
To learn more about the Military Health System Research Symposium, please visit: www.mhsrs.net. About PolarityTE® About SkinTE™ SkinTE is intended to be used by physicians or other appropriate healthcare providers for homologous uses of skin tissues/integument. Patients who have suffered from an event, disease, process or acquired deficit that results in the functional loss or void of skin/integument systems can receive SkinTE as an adjunct and/or in place of split-thickness skin grafting, full-thickness grafting, temporizing skin coverage and/or skin substitute products. SkinTE is for autologous use only. Aseptic technique during harvest and deployment of SkinTE is mandatory. SkinTE is marketed as an HCT/P regulated by the FDA solely under Section 361 of the Public Health Service Act and 21 CFR 1271. About OsteoTE™ OsteoTE is intended to be used by physicians or other appropriate healthcare providers for the homologous use of bone. OsteoTE is for autologous use only. Aseptic technique during harvest and deployment of OsteoTE is mandatory. OsteoTE is a human cells, tissues, and cellular and tissue-based product (HCT/P) registered with the FDA under Section 361 of the Public Health Service Act and 21 CFR 1271. Forward Looking Statements POLARITYTE, the POLARITYTE logo, WHERE SELF REGENERATES SELF, WELCOME TO THE SHIFT, SKINTE and OSTEOTE are trademarks or registered trademarks of PolarityTE, Inc. CONTACTS Investors: Hans Vitzthum Media: Government: View original content to download multimedia:http://www.prnewswire.com/news-releases/polarityte-to-present-at-military-health-system-research-symposium-on-platform-technology-for-treatment-of-traumatic-and-chronic-wounds-300902857.html SOURCE PolarityTE, Inc. | ||
Company Codes: NASDAQ-NMS:PTE |
© 2019 PR Newswire. All Rights Reserved.